Physician profile
Gary Bronstein
NPI 1932284528
$3,084.67
in general payments reported to CMS, 2019-2025
27 companies · $903 in 2025
The $903 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $763 · 2020: $276 · 2021: $99.12 · 2022: $129 · 2023: $397 · 2024: $518 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,817.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $767.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $373.71 | 2019-2025 | Farxiga, Lokelma |
| Pfizer INC. | $363.33 | 2019-2025 | |
| Cook Medical LLC | $149.49 | 2019 | |
| Abbott Laboratories | $145.46 | 2022-2024 | Mitraclip |
| Amgen INC. | $124.76 | 2019-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $121.97 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $111.26 | 2019-2025 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $108.90 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $108.89 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $90.90 | 2024-2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $86.86 | 2020-2025 | Amvuttra |
| Kowa Pharmaceuticals America, INC. | $77.19 | 2019-2023 | Livalo |
| Actelion Pharmaceuticals US, INC. | $70.69 | 2025 | Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.07 | 2019-2023 | Jardiance |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $53.27 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Regeneron Healthcare Solutions, INC. | $48.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.30 | 2025 | |
| Kiniksa Pharmaceuticals, LTD. | $41.89 | 2022-2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $26.14 | 2023 | Inpefa |
| Amarin Pharma, INC. | $22.15 | 2020 | |
| Kiniksa Pharmaceuticals International, Plc | $21.36 | 2024 | Arcalyst |
| W. L. Gore & Associates, INC. | $20.92 | 2021 | |
| Shionogi INC | $14.35 | 2019 | |
| Esperion Therapeutics, INC. | $13.24 | 2024 | Nexletol |
| Janssen Scientific Affairs, LLC | $12.20 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Bronstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.